Neurostimulation is moving fast, and the latest dataset hints at why the market is no longer just about devices but about delivery, evidence, and long-term outcomes working together. In 2023, neurostimulation devices generated an estimated $5.4 billion in global revenue, while adoption signals across pathways are widening, from TMS session uptake within care programs to growing hospital use for pain management. Pair that momentum with double digit growth forecasts for DBS and TMS through 2032 and you get a clear tension worth unpacking, especially as MRI conditional labeling, burst and waveform adoption, and closed loop research reshape what “standard of care” looks like.
Key Takeaways
- Breakdown of neuromodulation therapy types in market research: implantable DBS/SCS and non-invasive TMS/tDCS collectively represent the bulk of commercial activity, with each segment reported as multi-billion-dollar categories
- Burst stimulation and high-frequency SCS have reached market adoption and are represented as distinct product categories in industry reports (measurable by multi-billion SCS growth with waveforms adoption)
- MRI conditional labeling for many implantable neuromodulation systems is increasingly standard; FDA labeling lists include MRI-conditional constraints for certain devices
- 9.9% CAGR forecast for the DBS market from 2024 to 2032, reflecting growth expectations driven by indications and technological adoption
- 13.8% CAGR forecast for the TMS market from 2024 to 2032, capturing anticipated adoption growth for treatment and services
- $5.4 billion global revenue for neurostimulation devices in 2023 (estimate), reflecting the size of the neuromodulation-adjacent implant market.
- 9.5% of patients with Parkinson’s disease have received DBS or other surgical procedures in the US (as of 2014 clinical adoption survey estimates), reflecting penetration of surgical neuromodulation among eligible populations
- Electroconvulsive therapy (ECT) has well-established efficacy, with remission rates commonly reported around 50% in clinical studies, illustrating historical neuromodulation effectiveness (ECT modality benchmark)
- Meta-analysis evidence reports that deep brain stimulation improves motor symptoms in Parkinson’s disease compared with medical management alone (average standardized improvement reported across trials), supporting DBS clinical effectiveness
- ISO 13485 is the internationally recognized standard for medical device quality management systems and is commonly required by neuromodulation manufacturers for certification
- EU MDR (Regulation (EU) 2017/745) sets conformity and post-market requirements that apply to neuromodulation devices marketed in the European Union
- WHO reports that medical technologies are a key part of health systems, and regulatory frameworks are needed for safe adoption—context for neuromodulation oversight
- In the UK, NICE publishes technology appraisals and interventional procedures guidance that can affect National Health Service access to neuromodulation treatments
- France’s Haute Autorité de Santé (HAS) provides clinical value assessments that affect reimbursement decisions for technologies including neuromodulation devices
- Clinical cost-effectiveness analyses commonly report cost per QALY for neuromodulation interventions compared with alternatives, influencing payer adoption criteria
Implantable DBS and SCS plus noninvasive TMS and tDCS are driving rapid growth with rising clinical reach.
Related reading
01 · Category
Industry Trends9 stats
01
Breakdown of neuromodulation therapy types in market research: implantable DBS/SCS and non-invasive TMS/tDCS collectively represent the bulk of commercial activity, with each segment reported as multi-billion-dollar categories
02
Burst stimulation and high-frequency SCS have reached market adoption and are represented as distinct product categories in industry reports (measurable by multi-billion SCS growth with waveforms adoption)
03
MRI conditional labeling for many implantable neuromodulation systems is increasingly standard; FDA labeling lists include MRI-conditional constraints for certain devices
04
Remote monitoring and programming capabilities are increasingly emphasized in neuromodulation device roadmaps; connected device features are expanding across major manufacturers (measured by product release notes and FDA listings)
05
Algorithmic optimization and closed-loop research in DBS is progressing; systematic reviews report growing numbers of closed-loop neuromodulation studies over recent years
06
Non-invasive neuromodulation is being studied for cognitive and rehabilitation indications; the number of trials for TMS in stroke rehabilitation has increased in recent years (trial record counts on registries)
07
Clinical guidance increasingly includes personalized programming and dosing; clinical practice reviews report individualized parameter selection as a core implementation metric
08
26.9% of Medicare beneficiaries received an initial TMS session within 60 days of starting a covered depression treatment pathway in 2022 (claims-based cohort measure).
09
34% of US hospitals reported using neuromodulation devices for pain management in 2022 (survey finding), indicating broadening institutional adoption.
Interpretation
Industry Trends Interpretation
Industry Trends in neuromodulation are accelerating with mainstream adoption signals, including 26.9% of Medicare beneficiaries getting an initial TMS session within 60 days of a covered depression pathway in 2022 and 34% of US hospitals reporting neuromodulation use for pain management, alongside rapid product and clinical maturation such as distinct high-frequency and burst SCS categories and expanding MRI conditional and connected device capabilities.
02 · Category
Market Size3 stats
01
9.9% CAGR forecast for the DBS market from 2024 to 2032, reflecting growth expectations driven by indications and technological adoption
02
13.8% CAGR forecast for the TMS market from 2024 to 2032, capturing anticipated adoption growth for treatment and services
03
$5.4 billion global revenue for neurostimulation devices in 2023 (estimate), reflecting the size of the neuromodulation-adjacent implant market.
Interpretation
Market Size Interpretation
The neuromodulation market is set to expand steadily with double digit growth rates through 2032, including a 9.9% CAGR for DBS and a 13.8% CAGR for TMS, on top of an estimated $5.4 billion in 2023 revenue for neurostimulation devices, underscoring that market size is being driven by both adoption and expanding treatment use.
03 · Category
Clinical Evidence10 stats
01
9.5% of patients with Parkinson’s disease have received DBS or other surgical procedures in the US (as of 2014 clinical adoption survey estimates), reflecting penetration of surgical neuromodulation among eligible populations
02
Electroconvulsive therapy (ECT) has well-established efficacy, with remission rates commonly reported around 50% in clinical studies, illustrating historical neuromodulation effectiveness (ECT modality benchmark)
03
Meta-analysis evidence reports that deep brain stimulation improves motor symptoms in Parkinson’s disease compared with medical management alone (average standardized improvement reported across trials), supporting DBS clinical effectiveness
04
Cochrane review evidence supports TMS for depression with statistically significant improvements versus sham in many trials, evidencing clinical benefit for neuromodulation
05
Randomized evidence indicates that iTBS TMS protocols can produce clinical response in treatment-resistant depression, with effect sizes reported relative to sham conditions
06
Systematic review estimates spinal cord stimulation yields clinically meaningful pain reduction in chronic neuropathic pain populations, quantifying improvements on validated pain scales
07
Long-term follow-up studies report sustained improvements after DBS in Parkinson’s disease over multiple years, demonstrating durability beyond initial implantation
08
Evidence base for VNS in treatment-resistant depression includes randomized controlled trials showing improved outcomes versus sham/controls, supporting neurostimulation efficacy
09
Clinical trials for auricular vagus nerve stimulation (aVNS) in major depressive disorder report measurable symptom improvements vs controls using standardized scales (HAM-D/MADRS-type endpoints)
10
A 2018–2023 period systematic review reports that transcranial direct current stimulation (tDCS) can produce changes in motor learning and neurorehabilitation outcomes quantified using standardized functional measures
Interpretation
Clinical Evidence Interpretation
Across clinical evidence, neuromodulation is moving from established benchmarks to broader real-world impact, with studies showing about 50% remission for ECT and DBS reaching 9.5% of US Parkinson’s patients by 2014 while meta analyses and systematic reviews continue to report statistically meaningful benefits across modalities.
04 · Category
Regulatory & Quality6 stats
01
ISO 13485 is the internationally recognized standard for medical device quality management systems and is commonly required by neuromodulation manufacturers for certification
02
EU MDR (Regulation (EU) 2017/745) sets conformity and post-market requirements that apply to neuromodulation devices marketed in the European Union
03
WHO reports that medical technologies are a key part of health systems, and regulatory frameworks are needed for safe adoption—context for neuromodulation oversight
04
IEC 60601-1 is a fundamental standard for basic safety and essential performance for medical electrical equipment, relevant to neuromodulation device safety and performance testing
05
IEC 60601-1-2 addresses electromagnetic compatibility for medical electrical equipment, directly relevant to system interference risks in neuromodulation
06
IEC 62304 specifies life-cycle requirements for medical device software, relevant to neuromodulation therapy planning, control algorithms, and device UI
Interpretation
Regulatory & Quality Interpretation
Regulatory and Quality expectations for neuromodulation are strongly standardized and EU-focused, with ISO 13485 and the EU MDR driving common certification and post-market rules while multiple core IEC standards such as IEC 60601-1, IEC 60601-1-2, and IEC 62304 cover the safety, electromagnetic compatibility, and software lifecycle needs that regulators look for.
More related reading
05 · Category
Cost & Access4 stats
01
In the UK, NICE publishes technology appraisals and interventional procedures guidance that can affect National Health Service access to neuromodulation treatments
02
France’s Haute Autorité de Santé (HAS) provides clinical value assessments that affect reimbursement decisions for technologies including neuromodulation devices
03
Clinical cost-effectiveness analyses commonly report cost per QALY for neuromodulation interventions compared with alternatives, influencing payer adoption criteria
04
In the US, Medicaid expands coverage to low-income populations, potentially improving access to covered neuromodulation therapies relative to uninsured care
Interpretation
Cost & Access Interpretation
Across Cost and Access, reimbursement and coverage pathways are increasingly shaping neuromodulation access as NICE and HAS decisions in the UK and France influence uptake, while cost effectiveness evidence using cost per QALY and US Medicaid expansion for low income populations determine whether patients can actually reach these therapies.
06 · Category
User Adoption10 stats
01
In the US, there are thousands of neuromodulation implant procedures annually (DBS, SCS), indicating established clinical adoption at population scale
02
Utilization of TMS is growing; surveys and registry data in the US report thousands of patients treated annually with TMS for depression
03
Deep brain stimulation use has grown over time; registry studies report increasing DBS implant volumes across years in North America and Europe
04
Spinal cord stimulation adoption increased as new stimulation waveforms (e.g., high-frequency and burst) entered practice; retrospective studies quantify rising procedure counts over time
05
Clinical adoption of responsive neurostimulation is reflected in increasing published case-series and registry reporting in epilepsy care
06
In the UK, increasing NHS adoption depends on local service development for TMS clinics; published commissioning guidance indicates service scaling targets
07
Home-based or outpatient delivery models for TMS increase throughput; clinical settings report scheduled session counts per week as adoption metric
08
Connected neuromodulation adoption is enabled by wireless and app-based programming; industry surveys quantify increases in “remote monitoring” capabilities across device portfolios
09
Number of neuromodulation-related clinical trials indexed on ClinicalTrials.gov exceeds 5,000 total records, reflecting broad research and adoption interest across indications (search-filtered index value)
10
In a global registry analysis, neuromodulation contributed to improved quality-of-life measures in chronic pain cohorts, with responders defined at a ≥50% reduction in pain (proportion reported in study dataset).
Interpretation
User Adoption Interpretation
User adoption is clearly moving into population scale as reflected by more than 5,000 neuromodulation clinical trials on ClinicalTrials.gov alongside thousands of annual DBS, SCS, and TMS treatments and steadily rising procedure volumes over time.
07 · Category
Safety & Outcomes2 stats
01
In a 2021–2023 cohort review, adverse event rates for deep brain stimulation surgery were reported as a percentage range across studies, with serious procedure-related complications captured in systematic review tables.
02
In epilepsy neuromodulation trials, responders are commonly defined using the percent reduction in seizure frequency relative to baseline, with responder proportions reported as percentages.
Interpretation
Safety & Outcomes Interpretation
Across 2021 to 2023 cohort and systematic review evidence for deep brain stimulation, safety is consistently summarized through reported adverse event percentage ranges and procedure related serious complication tables, while epilepsy neuromodulation outcomes are typically judged by responder rates as a percent seizure frequency reduction from baseline.
08 · Category
Cost Analysis2 stats
01
US Medicare coverage policy for coverage with evidence development (CED) produces measurable coverage reach; CED policies are published with numeric inclusion criteria and endpoint schedules.
02
In US claims data studies, TMS utilization is quantified as counts of treated patients per year and the distribution of treatment sessions per episode (numeric endpoints).
Interpretation
Cost Analysis Interpretation
From a cost analysis perspective, US Medicare CED policies are tied to measurable, numeric inclusion criteria and scheduled endpoints, and claims-based studies quantify TMS as treated patients per year plus the distribution of session counts per episode, making costs more predictable by linking coverage reach and utilization intensity to specific numbers.
Reference
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Margot Villeneuve. (2026, February 13). Neuromodulation Industry Statistics. Gitnux. https://gitnux.org/neuromodulation-industry-statistics
MLA
Margot Villeneuve. "Neuromodulation Industry Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/neuromodulation-industry-statistics.
Chicago
Margot Villeneuve. 2026. "Neuromodulation Industry Statistics." Gitnux. https://gitnux.org/neuromodulation-industry-statistics.
Sources & references
46 datasets cited across this report · attribution is report-level
+24 additional datasets cited (not shown individually)